ADVM-022

BIOLOGICAL4 trials

Sponsors

Adverum Biotechnologies, Inc.

Conditions

Diabetic Macular EdemaDiabetic RetinopathyNeovascular Age-related Macular DegenerationWet Age-related Macular Degeneration

Phase 1

ADVM-022 Intravitreal Gene Therapy for Wet AMD

CompletedNCT03748784

Adverum Biotechnologies, Inc.Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration

Start: 2018-11-14End: 2022-06-22Updated: 2023-08-08

Phase 2

Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]

Active, not recruitingNCT05536973

Adverum Biotechnologies, Inc.Neovascular Age-related Macular Degeneration

Start: 2022-08-23End: 2028-08-31Updated: 2025-08-22

Unknown Phase

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

Active, not recruitingNCT04645212

Adverum Biotechnologies, Inc.Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration

Start: 2020-12-14End: 2030-06-26Updated: 2026-02-10

Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)

Active, not recruitingNCT05607810

Adverum Biotechnologies, Inc.Diabetic Macular Edema, Diabetic Retinopathy

Start: 2022-08-10End: 2026-04-30Target: 22Updated: 2025-04-22

Related Papers

Nonclinical study of ixo-vec gene therapy for nAMD supports efficacy for a human dose of 6E10 vg/eye and staggered dosing of fellow eyes

Molecular Therapy — Methods & Clinical Development2025-02-105 citations

Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study.

2023-12-2239 citations

Viral Vector Technologies and Strategies: Improving on Nature

International Ophthalmology Clinics2021-07-015 citations